التفاصيل البيبلوغرافية
| العنوان: |
Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy. |
| المؤلفون: |
Ulu, Kadir, Aliyev, Emil, Könte, Elif Kılıç, Tanatar, Ayşe, Türkmen, Şeyma, Doğantan, Şeyda, Kızıldağ, Zehra, Demir, Belde Kasap, Yıldırım, Deniz Gezgin, Yener, Gülçin Otar, Öztürk, Kübra, Baba, Özge, Açarı, Ceyhun, Kılbaş, Gülşah, Taşkın, Sema Nur, Haşlak, Fatih, Çağlayan, Şengül, Bağlan, Esra, Dundar, Hatice Adıgüzel, Başaran, Özge |
| المصدر: |
Rheumatology; 2024 Supplement, Vol. 63, pSI167-SI172, 6p |
| مصطلحات موضوعية: |
BIOTHERAPY, CROSS-sectional method, JUVENILE idiopathic arthritis, PLATELET count, FERRITIN, DISEASE duration, SCIENTIFIC observation, ANTIRHEUMATIC agents, CHILDREN'S hospitals, RETROSPECTIVE studies, BLOOD sedimentation, FEVER, DRUG efficacy, RESEARCH, MEDICAL records, ACQUISITION of data, MACROPHAGE activation syndrome, CELL receptors, INTERLEUKINS, C-reactive protein, PHARMACODYNAMICS, CHEMICAL inhibitors |
| مستخلص: |
Objectives The aim of this study is to investigate the effect of anti-interleukin (IL)-1/-6 biologics on systemic juvenile idiopathic arthritis (sJIA)-associated macrophage activation syndrome (MAS). Methods Demographic, clinical and laboratory data of patients followed up with a diagnosis of sJIA-associated MAS assessed from sixteen paediatric rheumatology centres across the country. The clinical and laboratory features of MAS developing while on biological drugs were compared with those without this treatment. Results One hundred and sixty-two patients were included in the study. Forty-five of the MAS events were detected under the effect of anti-IL-1/-6 biologics, while the patients experiencing the remaining 155 events have not received biological treatment in the last three months. Platelet count [128 (72–232) vs 199 (130–371) 109/l], ferritin level on admission [1107 (676–2050) vs 2863 (1193–9562) ng/ml], C-reactive protein level [15.4 (2.9–56) vs 90 (32–160) mg/l], erythrocyte sedimentation rate [13 (3–36) vs 43.5 (13–77) mm/h] and fever duration [5 (4–7.5) vs 10 (7–14.3) days] were found lower in the group under the impact of anti-IL-1/-6 biologics. Among patients treated with biologics, 26.6% did not meet the published 2016 MAS classification criteria at presentation. The rates of hepatomegaly and splenomegaly were relatively lower in the canakinumab-treated group when compared with those receiving other biologicals or to patients, not on biologicals. Conclusion Anti-IL-1/-6 therapies can mask the clinical and laboratory features of MAS, and proposed guidelines for MAS classification criteria may not be met. [ABSTRACT FROM AUTHOR] |
|
Copyright of Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder